Canopy Growth Corporation introduces Spectrum Therapeutics, a new global brand that will encompass all of the Company's ongoing commercial medical and clinical research operations including Spectrum Cannabis, Canopy Health Innovations (CHI), and the most recent addition to Canopy Growth's medical portfolio, Bionorica SE-founded C3Cannabinoid Compound Company ("C3"), a European leader in cannabinoid-based medical therapies.
"Incorporating these entities into one unified ecosystem will integrate our medical efforts as one global healthcare enterprise. Spectrum Therapeutics now encompasses the production and distribution of full-spectrum and single cannabinoid medical cannabis products; industry-leading education, resources and support for patients and healthcare practitioners; as well as pre-clinical and clinical research and the development of cannabinoid-based medicines," the team with the company explains.
In addition to providing commercially available medical cannabis products on five continents, Spectrum Therapeutics will continue to offer medical cannabis education for patients and healthcare professionals in countries with legal regulatory frameworks. Through the continuation of CHI and C3's respective clinical research programs, Spectrum Therapeutics will also focus on the research and development of clinically ready cannabinoid drug formulations and dosage formats. In addition to supporting drug registration, this research also supports best-in-class physician and patient interaction and education for Spectrum Therapeutics' commercial operations on a global basis.
For more information: 
Canopy Growth
1 Hershey Dr.
Smiths Falls, Ontario
K7A 0A8
1 855 558 9333 x 122
invest@canopygrowth.com
www.canopygrowth.com